Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level

Journal of Cell Science

Volumn 119, Issue 16, 2006, Pages 3351-3362

  Hubert, Antoine ^a   Paris, Sébastien ^a   Piret, Jean Pascal ^a   Ninane, Noëlle ^a   Raes, Martine ^a   Michiels, Carine ^a  

^a UNIVERSITY OF NAMUR   (Belgium)

Author keywords

CK2; HIF 1; Hypoxia; MDM2; p53; Transcription regulation

Indexed keywords

CASEIN KINASE II; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MUTANT PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PIFITHRIN ALPHA; PROTEIN P53; SMALL INTERFERING RNA;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN INTERACTION; WILD TYPE;

CARCINOMA, HEPATOCELLULAR; CASEIN KINASE II; CELL HYPOXIA; CELLS, CULTURED; ENZYME INHIBITORS; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33748767112     PISSN: 00219533     EISSN: None     Source Type: Journal    
DOI: 10.1242/jcs.03069     Document Type: Article

References (74)

1. Achison, M. and Hupp, T. R. (2003). Hypoxia attenuates the p53 response to cellular damage. Oncogene 22, 3431-3440.
2. Ahmed, K., Gerber, D. A. and Cochet, C. (2002). Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol. 12, 226-230.
3. An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V. and Neckers, L. M. (1998). Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392, 405-408.
4. Arany, Z., Huang, L. E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg, M. A., Bunn, H. F. and Livingston, D. M. (1996). An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 93, 12969-12973.
5. Avantaggiati, M. L., Ogryzko, V., Gardner, K., Giordano, A., Levine, A. S. and Kelly, K. (1997). Recruitment of p300/CBP in p53-dependent signal pathways. Cell 89, 1175-1184.
6. Bassi, L., Carloni, M., Fonti, E., Palma de la Pena, N., Meschini, R. and Palitti, F. (2002). Pifithrin-alpha, an inhibitor of p53, enhances the genetic instability induced by etoposide (VP16) in human lymphoblastoid cells treated in vitro. Mutat. Res. 499, 163-176.
7. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T. and Neckers, L. (1998). p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273, 11995-11998.
8. Blaydes, J. P. and Hupp, T. R. (1998). DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene 17, 1045-1052.
9. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T. and Hannon, G. J. (1995). Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-557.
10. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P. et al. (1998). Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490.
11. Chen, D., Li, M., Luo, J. and Gu, W. (2003). Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J. Biol. Chem. 278, 13595-13598.
12. Critchfield, J. W., Coligan, J. E., Folks, T. M. and Butera, S. T. (1997). Casein kinase II is a selective target of HIV-1 transcriptional inhibitors. Proc. Natl. Acad. Sci. USA 94, 6110-6115.
13. el-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825.
14. Fang, J., Xia, C., Cao, Z., Zheng, J. Z., Reed, E. and Jiang, B. H. (2005). Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19, 342-353.
15. Farah, M., Parhar, K., Moussavi, M., Eivemark, S. and Salh, B. (2003). 5,6-Dichloro-ribifuranosylbenzimidazole- and apigenin-induced sensitization of colon cancer cells to TNF-alpha-mediated apoptosis. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G919-G928.
16. Fatyol, K. and Szalay, A. A. (2001). The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J. Biol. Chem. 276, 28421-28429.
17. Faust, R. A., Niehans, G., Gapany, M., Hoistad, D., Knapp, D., Cherwitz, D., Davis, A., Adams, G. L. and Ahmed, K. (1999). Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int. J. Biochem. Cell Biol. 31, 941-949.
18. Fontanini, G., Boldrini, L., Vignati, S., Chine, S., Basolo, F., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A. and Bevilacqua, G. (1998). Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur. J. Cancer 34, 718-723.
19. Ford, H. L., Landesman-Bollag, E., Dacwag, C. S., Stukenberg, P. T., Pardee, A. B. and Seldin, D. C. (2000). Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J. Biol. Chem. 275, 22245-22254.
20. Giaccia, A. J. and Kastan, M. B. (1998). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12, 2973-2983.
21. Gu, W., Shi, X. L. and Roeder, R. G. (1997). Synergistic activation of transcription by CBP and p53. Nature 387, 819-823.
22. Hammond, E. M., Denko, N. C., Dorie, M. J., Abraham, R. T. and Giaccia, A. J. (2002). Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22, 1834-1843.
23. Hansson, L. O., Friedler, A., Freund, S., Rudiger, S. and Fersht, A. R. (2002). Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. Proc. Natl. Acad. Sci. USA 99, 10305-10309.
24. Hanyaloglu, A. C., Vrecl, M., Kroeger, K. M., Miles, L. E., Qian, H., Thomas, W. G. and Eidne, K. A. (2001). Casein kinase II sites in the intracellular C-terminal domain of the thyrotropin-releasing hormone receptor and chimeric gonadotropin-releasing hormone receptors contribute to beta-arrestin-dependent internalization. J. Biol. Chem. 276, 18066-18074.
25. Harris, C. C. (1996). p53 tumor suppressor gene: from the basic research laboratory to the clinic-an abridged historical perspective. Carcinogenesis 17, 1187-1198.
26. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in human cancers. Science 253, 49-53.
27. Hopfl, G., Ogunshola, O. and Gassmann, M. (2004). HIFs and tumors-causes and consequences. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286, R608-R623.
28. Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F. and Neckers, L. M. (2002). Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277, 29936-29944.
29. Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S. and Kaelin, W. G., Jr (2001). HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464-468.
30. Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A., Hebestreit, H. F., Mukherji, M., Schofield, C. J. et al. (2001). Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468-472.
31. Jain, R. K. (2003). Molecular regulation of vessel maturation. Nat. Med. 9, 685-693.
32. Kaluzova, M., Kaluz, S., Lerman, M. I. and Stanbridge, E. J. (2004). DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX. Mol. Cell. Biol. 24, 5757-5766.
33. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W. and Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830.
34. Komarov, P. G., Komarova, E. A., Kondratov, R. V., Christov-Tselkov, K., Coon, J. S., Chernov, M. V. and Gudkov, A. V. (1999). A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733-1737.
35. Koumenis, C., Alarcon, R., Hammond, E., Sutphin, P., Hoffman, W., Murphy, M., Derr, J., Taya, Y., Lowe, S. W., Kastan, M. et al. (2001). Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell. Biol. 21, 1297-1310.
36. Landesman-Bollag, E., Romieu-Mourez, R., Song, D. H., Sonenshein, G. E., Cardiff, R. D. and Seldin, D. C. (2001). Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20, 3247-3257.
37. Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. and Whitelaw, M. L. (2002). Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295, 858-861.
38. Levine, A. J. (1997). p53, the cellular gatekeeper for growth and division. Cell 88, 323-331.
39. Litchfield, D. W. (2003). Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369, 1-15.
40. Mahon, P. C., Hirota, K. and Semenza, G. L. (2001). FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686.
41. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., Hankinson, O., Pugh, C. W. and Ratcliffe, P. J. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94, 8104-8109.
42. McKendrick, L., Milne, D. and Meek, D. (1999). Protein kinase CK2-dependent regulation of p53 function: evidence that the phosphorylation status of the serine 386 (CK2) site of p53 is constitutive and stable. Mol. Cell. Biochem. 191, 187-199.
43. Michel, G., Minet, E., Mottet, D., Remacle, J. and Michiels, C. (2002). Site-directed mutagenesis studies of the hypoxia-inducible factor-1alpha DNA-binding domain. Biochim. Biophys. Acta 1578, 73-83.
44. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle, J. and Michiels, C. (1999). Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 460, 251-256.
45. Minet, E., Arnould, T., Michel, G., Roland, I., Mottet, D., Raes, M., Remacle, J. and Michiels, C. (2000). ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 468, 53-58.
46. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B. and Reed, J. C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799-1805.
47. Mottet, D., Michel, G., Renard, P., Ninane, N., Raes, M. and Michiels, C. (2003). Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J. Cell Physiol. 194, 30-44.
48. Mottet, D., Pyr Dit Rys, S., Demazy, C., Raes, M. and Michiels, C. (2005). A role for casein kinase 2 in the regulation of HIF-1 activity. Int. J. Cancer 117, 764-774.
49. Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M. et al. (1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188, 2033-2045.
50. Munstermann, U., Fritz, G., Seitz, G., Lu, Y. P., Schneider, H. R. and Issinger, O. G. (1990). Casein kinase II is elevated in solid human tumours and rapidly proliferating non-neoplastic tissue. Eur. J. Biochem. 189, 251-257.
51. Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J. and Simon, M. C. (2004). p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment. Oncogene 23, 4975-4983.
52. Piret, J. P., Mottet, D., Raes, M. and Michiels, C. (2002). Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem. Pharmacol. 64, 889-892.
53. Qin, J. Z., Chaturvedi, V., Denning, M. F., Bacon, P., Panella, J., Choubey, D. and Nickoloff, B. J. (2002). Regulation of apoptosis by p53 in UV-irradiated human epidermis, psoriatic plaques and senescent keratinocytes. Oncogene 21, 2991-3002.
54. Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L. and Bedi, A. (2000). Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34-44.
55. Renard, P., Ernest, I., Houbion, A., Art, M., Le Calvez, H., Raes, M. and Remacle, J. (2001). Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 29, E21.
56. Richard, D. E., Berra, E., Gothie, E., Roux, D. and Pouyssegur, J. (1999). p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274, 32631-32637.
57. Rocha, S., Campbell, K. J., Roche, K. C. and Perkins, N. D. (2003). The p53-inhibitor pifithrin-alpha inhibits firefly luciferase activity in vivo and in vitro. BMC Mol. Biol. 4, 9.
58. Ruzzene, M., Penzo, D. and Pinna, L. A. (2002). Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem. J. 364, 41-47.
59. Sanchez-Puig, N., Veprintsev, D. B. and Fersht, A. R. (2005). Binding of natively unfolded HIF-1 alpha ODD domain to p53. Mol. Cell 17, 11-21.
60. Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V. and Caro, J. (2003). MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. J. Biol. Chem. 278, 14013-14019.
61. Schmid, T., Zhou, J., Kohl, R. and Brune, B. (2004). p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem. J. 380, 289-295.
62. Semenza, G. L. (2000). HIF-1 and human disease: one highly involved factor. Genes Dev. 14, 1983-1991.
63. Semenza, G. L. (2003). Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3, 721-732.
64. Semenza, G. L., Jiang, B. H., Leung, S. W., Passantino, R., Concordet, J. P., Maire, P. and Giallongo, A. (1996). Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271, 32529-32537.
65. Shen, J., Channavajhala, P., Seldin, D. C. and Sonenshein, G. E. (2001). Phosphorylation by the protein kinase CK2 promotes calpain-mediated degradation of IkappaBalpha. J. Immunol. 167, 4919-4925.
66. Toillon, R. A., Chopin, V., Jouy, N., Fauquette, W., Boilly, B. and Le Bourhis, X. (2002). Normal breast epithelial cells induce p53-dependent apoptosis and p53-independent cell cycle arrest of breast cancer cells. Breast Cancer Res. Treat. 71, 269-280.
67. Waldman, T., Kinzler, K. W. and Vogelstein, B. (1995). p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55, 5187-5190.
68. Wei, N. and Deng, X. W. (2003). The COP9 signalosome. Annu. Rev. Cell Dev. Biol. 19, 261-286.
69. Wenger, R. H. (2002). Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 16, 1151-1162.
70. Winer, J., Jung, C. K., Shackel, I. and Williams, P. M. (1999). Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal. Biochem. 270, 41-49.
71. Wolf, D. A., Zhou, C. and Wee, S. (2003). The COP9 signalosome: an assembly and maintenance platform for cullin ubiquitin ligases? Nat. Cell Biol. 5, 1029-1033.
72. Yap, D. B., Hsieh, J. K., Zhong, S., Heath, V., Gusterson, B., Crook, T. and Lu, X. (2004). Ser392 phosphorylation regulates the oncogenic function of mutant p53. Cancer Res. 64, 4749-4754.
73. Zhu, C. C., Cook, L. B. and Hinkle, P. M. (2002). Dimerization and phosphorylation of thyrotropin-releasing hormone receptors are modulated by agonist stimulation. J. Biol. Chem. 277, 28228-28237.
74. Zien, P., Abramczyk, O., Domanska, K., Bretner, M. and Szyszka, R. (2003). TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications. Biochem. Biophys. Res. Commun. 312, 623-628.